Development and characterization of a potent immunoconjugate targeting the Fn14 receptor on solid tumor cells

Molecular Cancer Therapeutics

Volumn 10, Issue 7, 2011, Pages 1276-1288

  Zhou, Hong ^a   Marks, John W ^a   Hittelman, Walter N ^a   Yagita, Hideo ^c   Cheung, Lawrence H ^a   Rosenblum, Michael G ^a   Winkles, Jeffrey A ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DNA NUCLEOTIDYLEXOTRANSFERASE; FIBROBLAST GROWTH FACTOR 14; GELONIN; HIGH MOBILITY GROUP B1 PROTEIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY FN14; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY AFFINITY; ANTIGEN BINDING; APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER TUMOR; BRAIN CANCER; BREAST CANCER; CANCER INHIBITION; COLON CANCER; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG PROTEIN BINDING; FEMALE; IC 50; INTERNALIZATION; LUNG CANCER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SKIN CANCER; SOLID TUMOR; TUMOR CELL; TUMOR LOCALIZATION; TUMOR MODEL; TUMOR VOLUME; UTERINE CERVIX CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HMGB1 PROTEIN; HT29 CELLS; HUMANS; IMMUNOCONJUGATES; INJECTIONS, INTRAVENOUS; JURKAT CELLS; MICE; MICE, NUDE; NEOPLASMS; PROTEIN BINDING; RECEPTORS, TUMOR NECROSIS FACTOR; RIBOSOME INACTIVATING PROTEINS, TYPE 1; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960124328     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-11-0161     Document Type: Article

References (50)

1. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008;7: 411-25. (Pubitemid 351619113)
2. Winkles JA, Tran NL, Brown SA, Stains N, Cunliffe HE, Berens ME. Role of TWEAK and Fn14 in tumor biology. Front Biosci 2007; 12:2761-71.
3. Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, et al. Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol 2003;170:341-8. (Pubitemid 36026158)
4. Wang D, Fung JN, Tuo Y, Hu L, Chen C. TWEAK/Fn14 promotes apoptosis of human endometrial cancer cells via caspase pathway. Cancer Lett 2010;294:91-100.
5. Tran NL, McDonough WS, Donohue PJ, Winkles JA, Berens TJ, Ross KR, et al. The human Fn14 receptor gene is up-regulated in migrating glioma cells in vitro and overexpressed in advanced glial tumors. Am J Pathol 2003;162:1313-21. (Pubitemid 36350675)
6. Fortin SP, Ennis MJ, Savitch BA, Carpentieri D, McDonough WS, Winkles JA, et al. Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function. Mol Cancer Res 2009;7:1871-81.
7. Tran NL, McDonough WS, Savitch BA, Sawyer TF, Winkles JA, Berens ME. The tumor necrosis factor-like weak inducer of apoptosis (TWEAK)-fibroblast growth factor-inducible 14 (Fn14) signaling system regulates glioma cell survival via NFkappaB pathway activation and BCL-XL/BCL-W expression. J Biol Chem 2005;280:3483-92. (Pubitemid 40223813)
8. Culp PA, Choi D, Zhang Y, Yin J, Seto P, Ybarra SE, et al. Antibodies to TWEAK receptor inhibit human tumor growth through dual mechanisms. Clin Cancer Res 2010;16:497-508.
9. Tran NL, McDonough WS, Savitch BA, Fortin SP, Winkles JA, Symons M, et al. Increased fibroblast growth factor-inducible 14 expression levels promote glioma cell invasion via Rac1 and nuclear factor-kappaB and correlate with poor patient outcome. Cancer Res 2006; 66:9535-42. (Pubitemid 44623652)
10. Wang S, Zhan M, Yin J, Abraham JM, Mori Y, Sato F, et al. Transcriptional profiling suggests that Barrett's metaplasia is an early intermediate stage in esophageal adenocarcinogenesis. Oncogene 2006;25:3346-56. (Pubitemid 43846319)
11. Watts GS, Tran NL, Berens ME, Bhattacharyya AK, Nelson MA, Montgomery EA, et al. Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma. Int J Cancer 2007;121:2132-9. (Pubitemid 47585591)
12. Willis AL, Tran NL, Chatigny JM, Charlton N, Vu H, Brown SA, et al. The fibroblast growth factor-inducible 14 receptor is highly expressed in HER2-positive breast tumors and regulates breast cancer cell invasive capacity. Mol Cancer Res 2008;6:725-34.
13. Michaelson JS, Burkly LC. Therapeutic targeting of TWEAK/Fnl4 in cancer: exploiting the intrinsic tumor cell killing capacity of the pathway. Results Probl Cell Differ 2009;49:145-60.
14. Stumpp MT, Binz HK, Amstutz P. DARPins: a new generation of protein therapeutics. Drug Discov Today 2008;13:695-701.
15. Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009;13:245-55.
16. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008;14:154-69.
17. Gerber HP, Senter PD, Grewal IS. Antibody drug-conjugates targeting the tumor vasculature: current and future developments. MAbs 2009;1:247-53.
18. Zhou H, Liu Y, Cheung LH, Kim S, Zhang W, Mohamedali KA, et al. Characterization and mechanistic studies of a novel melanoma-targeting construct containing IkappaBa for specific inhibition of nuclear factor-kappaB activity. Neoplasia 2010;12:766-77.
19. Brown SA, Hanscom HN, Vu H, Brew SA, Winkles JA. TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules. Biochem J 2006;397:297-304. (Pubitemid 44076899)
20. Geft D, Schwartzenberg S, Rogowsky O, Finkelstein A, Ablin J, Maysel-Auslender S, et al. Circulating apoptotic progenitor cells in patients with congestive heart failure. PLoS One 2008;3:e3238.
21. Thorburn J, Horita H, Redzic J, Hansen K, Frankel AE, Thorburn A. Autophagy regulates selective HMGB1 release in tumor cells that are destined to die. Cell Death Differ 2009;16:175-83.
22. Rosenblum MG, Cheung LH, Liu Y, Marks JW III. Design, expression, purification, and characterization, in vitro and in vivo, of an antimelanoma single-chain Fv antibody fused to the toxin gelonin. Cancer Res 2003;63:3995-4002. (Pubitemid 36917918)
23. Nakayama M, Harada N, Okumura K, Yagita H. Characterization of murine TWEAK and its receptor (Fn14) by monoclonal antibodies. Biochem Biophys Res Commun 2003;306:819-25. (Pubitemid 36776204)
24. Scaffidi P, Misteli T, Bianchi ME. Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature 2002;418:191-5. (Pubitemid 34773774)
25. Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets 2010;14:1091-108.
26. Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ. Targeting death-inducing receptors in cancer therapy. Oncogene 2007;26:3745-57. (Pubitemid 46842709)
27. Croft M. The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol 2009;9:271-85.
28. Tamada K, Chen L. Renewed interest in cancer immunotherapy with the tumor necrosis factor superfamily molecules. Cancer Immunol Immunother 2006;55:355-62. (Pubitemid 43076887)
29. Debatin KM, Krammer PH. Death receptors in chemotherapy and cancer. Oncogene 2004;23:2950-66. (Pubitemid 38638855)
30. Mahmood Z, Shukla Y. Death receptors: targets for cancer therapy. Exp Cell Res 2010;316:887-99.
31. Ashkenazi A. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nat Rev Drug Discov 2008;7:1001-12.
32. Dai L, Gu L, Ding C, Qiu L, Di W. TWEAK promotes ovarian cancer cell metastasis via NF-kappaB pathway activation and VEGF expression. Cancer Lett 2009;283:159-67.
33. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999;274:8455-9. (Pubitemid 29164634)
34. Clouser M, Hess LM, Chambers SK. Biomarker targets and novel therapeutics. Cancer Treat Res 2009;149:85-105.
35. Farley J, Birrer MJ. Novel therapeutic targets. Cancer Treat Res 2009;149:63-84.
36. Vincenzi B, Zoccoli A, Pantano F, Venditti O, Galluzzo S. Cetuximab: from bench to bedside. Curr Cancer Drug Targets 2010;10:80-95.
37. Gialeli C, Kletsas D, Mavroudis D, Kalofonos HP, Tzanakakis GN, Karamanos NK. Targeting epidermal growth factor receptor in solid tumors: critical evaluation of the biological importance of therapeutic monoclonal antibodies. Curr Med Chem 2009;16:3797-804.
38. Advani A, Coiffier B, Czuczman MS, Dreyling M, Foran J, Gine E, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010;28:2085-93.
39. + metastatic breast cancer. Curr Opin Mol Ther 2010;12:350-60.
40. Okeley NM, Miyamoto JB, Zhang X, Sanderson RJ, Benjamin DR, Sievers EL, et al. Intracellular activation of SGN-35, a potent anti-CD30 antibody-drug conjugate. Clin Cancer Res 2010;16: 888-97.
41. Polson AG, Williams M, Gray AM, Fuji RN, Poon KA, McBride J, et al. Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma. Leukemia 2010;24:1566-73.
42. Risberg K, Fodstad O, Andersson Y. Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells. J Immunother 2010;33:272-8.
43. Zhou XX, Ji F, Zhao JL, Cheng LF, Xu CF. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells. J Gastroenterol Hepatol 2010;25:1266-75.
44. Rosenblum MG, Barth S. Development of novel, highly cytotoxic fusion constructs containing granzyme B: unique mechanisms and functions. Curr Pharm Des 2009;15:2676-92.
45. Preijers FW, Tax WJ, De WT, Janssen A, vd HH, Vidal H, et al. Relationship between internalization and cytotoxicity of ricin A-chain immunotoxins. Br J Haematol 1988;70:289-94. (Pubitemid 18265246)
46. Recht LD, Raso V, Davis R, Salmonsen R. Immunotoxin sensitivity of Chinese hamster ovary cells expressing human transferrin receptors with differing internalization rates. Cancer Immunol Immunother 1996;42:357-61. (Pubitemid 26298123)
47. Pirie CM, Hackel BJ, Rosenblum MG, Wittrup KD. Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties. J Biol Chem 2011;286: 4165-72.
48. Lyu MA, Rai D, Ahn KS, Sung B, Cheung LH, Marks JW, et al. The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo. Neoplasia 2010;12:366-75.
49. Cao Y, Marks JD, Marks JW, Cheung LH, Kim S, Rosenblum MG. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies. Cancer Res 2009;69:8987-95.
50. Kalinina N, Agrotis A, Antropova Y, DiVitto G, Kanellakis P, Kostolias G, et al. Increased expression of the DNA-binding cytokine HMGB1 in human atherosclerotic lesions: role of activated macrophages and cytokines. Arterioscler Thromb Vasc Biol 2004;24:2320-5. (Pubitemid 39658036)